Myeloid-Derived Suppressor Cells in Infection: A General Overview

Eva Medina\textsuperscript{a} Dominik Hartl\textsuperscript{b}

\textsuperscript{a}Helmholtz Centre for Infection Research, Infection Immunology Research Group, Braunschweig, Germany; \textsuperscript{b}Children’s Hospital, University of Tübingen, Tübingen, Germany

\section*{Keywords}
Myeloid-derived suppressor cells · Infections · Monocytic-myeloid-derived suppressor cells · PMN-myeloid-derived suppressor cells · Eo-myeloid-derived suppressor cells

\section*{Abstract}
After initial infection, the immune response that serves to restrict the invading pathogen needs to be tightly calibrated in order to avoid collateral immunopathological damage. This calibration is performed by specialized suppressor mechanisms, which are capable of dampening overwhelming or unremitting inflammation in order to prevent tissue damage. Myeloid-derived suppressor cells (MDSC) are emerging as key players in counter-balancing inflammatory responses and pathogenesis during infection. However, some pathogens are able to exploit the suppressive activities of MDSC to favor pathogen persistence and chronic infections. In this article, we review the current knowledge about the importance of MDSC in the context of bacterial, virus, parasites, and fungal infections.

\section*{Myeloid-Derived Suppressor Cells}
Myeloid-derived suppressor cells (MDSC) are a highly heterogeneous cell population with strong immunosuppressive effects on T-cell responses [1]. MDSC arise from common myeloid progenitors and are arrested in an immature phase of differentiation [1]. The frequency of MDSC in steady-state conditions is very low but increases dramatically in pathological conditions such as cancer, autoimmunity, and infection [2]. Although MDSC are phenotypically and functionally very heterogeneous, different MDSC subsets have been identified based on the expression of distinct cell surface markers. Traditionally, MDSC have been classified as monocytic CD11b\textsuperscript{+}Ly6C\textsuperscript{+}Ly6G\textsuperscript{low} (M-MDSC) or granulocytic CD11b\textsuperscript{+}Ly6C\textsuperscript{low}Ly6G\textsuperscript{+} (PMN-MDSC) based on the Ly6C and Ly6G expression levels [2]. Recently, a new subset of MDSC has been identified in mice with chronic Staphylococcus aureus infection that was termed Eo-MDSC because they depicted phenotypic features typical of immature eosinophils including CD11b\textsuperscript{+}Syglec-F\textsuperscript{+}CCR3\textsuperscript{low}IL-5Ra\textsuperscript{low}SSC-A\textsuperscript{high} [3]. Phenotypic markers for human MDSC subsets in peripheral blood include CD11b\textsuperscript{+}CD14\textsuperscript{+}CD15\textsuperscript{+} or CD11b\textsuperscript{+}CD14\textsuperscript{+}CD66b\textsuperscript{+}
for PMN-MDSC, CD11b⁺CD14⁺HLA-DR⁻lowCD15⁻ for M-MDSC, and Lin⁻HLA-DR⁻CD33⁺ for more immature MDSC progenitors [4].

Major drivers for MDSC expansion under pathological conditions are inflammatory factors such as prostaglandin E2 [5], pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6), and IL-1β [6] and myeloid-related calgranulin B (S100A9) [7] among others. MDSC exercise their immunosuppressive activities through various mechanisms, including the generation of high levels of inducible nitric oxide (iNOS, mainly M-MDSC) and reactive oxygen species (ROS, mainly PMN-MDSC) that induce the nitration of the T-cell receptor and prevent its interaction with cognate antigen-major histocompatibility complex (MHC) [8], as well as by the production of arginase-1 that in combination with high levels of iNOS restricts the availability of the amino acid L-arginine, which is essential for T-cell proliferation [9]. It has been suggested that the usage of each mechanism may depend on the specific MDSC subset and the site of immunosuppression [10].

Condamine and Gabrilovich [11] proposed a model to explain why the release of inflammatory mediators during acute inflammation does not result in the expansion and accumulation of MDSC. The proposed model involved 2 steps, the first step is mediated by cytokines (e.g., IL-6) and growth factors (e.g., granulocyte-macrophage colony-stimulating factor [GM-CSF], macrophage CSF, granulocyte CSF) produced during chronic inflammation that prevent differentiation of immature myeloid cells and drive expansion of MDSC via signaling through the transcription factors signal transducer and activator of transcription 3 (STAT3) and STAT5 [11]. The second step is mediated by proinflammatory cytokines such as interferon gamma (IFNγ) and IL-1β as well as by toll-like receptor (TLR) ligands that induce the upregulation of immunosuppressive mechanisms in MDSC (e.g., arginase and nitric oxide [NO]) via STAT1 and NF-κB transcription factors [11].

While initial studies with MDSC focused on their role in tumor biology, accumulating evidence indicates an important role for MDSC in the control of immune responses to pathogens [12]. MDSC can be of benefit to the host by reducing immune-mediated pathology that can result as collateral damage associated with a robust host immune response to the pathogen. On the other hand, because their remarkable capacity to suppress effector T-cells, MDSC can prevent the immune system from mounting an effective immune response, thus favoring pathogen persistence and chronic infection. In the next sections, we address the role of MDSC in bacterial, viral, parasites, and fungal infections (summarized in Table 1).

**MDSC in Bacterial Infections**

Based on a clinical study performed in patients with septic shock and sepsis caused by Gram-negative and Gram-positive bacteria, Janols et al. [13] suggested that different bacteria can induce distinct MDSC subsets. Thus, whereas the frequency of M-MDSC determined by the phenotypic markers CD14⁺HLA-DRlow was very high in all sepsis patients, increased proportion of PMN-MDSC (CD14low) with strong immunosuppressive effect was observed preferentially in patients infected with Gram-positive bacteria [13]. The authors suggested that release of immature myeloid cells phenotypically and functionally resembling PMN-MDSC from bone marrow is largely induced by Gram-positive but not by Gram-negative sepsis [13]. In this regard, it has been proposed that the observed difference in MDSC subsets in septic patients may be the consequence of fundamental differences in the host responses to Gram-positive and Gram-negative bacterial infections [14]. Thus, Gram-negative pathogens generally induce stronger inflammatory responses than Gram-positive resulting in fast mobilization of bone marrow bactericidal neutrophils rather than immunosuppressive PMN-MDSC [14]. Gram-positive, on the other hand, induce a milder and more prolonged inflammatory reaction that favor the expansion of immunosuppressive PMN-MDSC [14]. The influence of the magnitude of the inflammatory response to infection for the generation and activity of MDSC has been currently demonstrated in an experimental model of lethal pulmonary tularemia [15]. The authors demonstrated that infection caused by highly virulent Francisella tularensis, a Gram-negative intracellular pathogen classified as category A bio-threat agent, induced the recruitment of a large amount of MDSC to the lungs and spleens that eventually led to organ damage and host death, whereas the host response to sub-lethal F. tularensis infection was associated with the recruitment of mature myeloid cells leading to bacterial clearance and host survival [15].

A functional correlation between MDSCs frequency and infection phase and duration was demonstrated in patients with tuberculosis, a highly contagious infection of the lungs caused by the Gram-positive bacterium Mycobacterium tuberculosis and the most common cause of disease-related mortality worldwide [16]. Thus, high frequencies of MDSC with strong immunosuppressive effect on protective T-cell responses were detected in peripheral blood in tuberculosis patients and at the site of infection in tuberculosis pleuritic cases [16]. However, MDSC from long-term tuberculosis patients induced
more extensive suppressive effect on T-cell responses than those from healthy individuals recently exposed to *M. tuberculosis* [16]. Interestingly, the authors also reported that the frequency of MDSC returned to the levels and maturation status of healthy individuals after successful antibiotic treatment and concluded that MDSC induced after exposure to *M. tuberculosis* may contribute to the inability of the host to eliminate the bacterium and thus to disease development [16]. Association of MDSC expansion with tuberculosis progression has also been observed in murine models of *M. tuberculosis* infection [17, 18]. Specifically, Tsiganov et al. [17] reported that

| Infection category | Organism | Infection type | Effect | References |
|-------------------|----------|----------------|--------|------------|
| **Bacterial infections** | *Francisella tularensis* | Mouse Lung infection (intranasal inoculation) | Detrimental | [15] |
| Mycobacterium tuberculosis | Human Lung infection | Detrimental | [16] |
| Mycobacterium tuberculosis | Mouse Lung infection (intratracheal inoculation) | Detrimental | [17] |
| Mycobacterium tuberculosis | Mouse Lung infection (aerosol inoculation) | Detrimental | [18] |
| Salmonella typhimurium | Mouse Intestinal infection (intragastric inoculation) | Beneficial at low frequency and detrimental at high frequency | [19] |
| Staphylococcus aureus | Mouse Chronic abscess (intravenous inoculation) | Detrimental | [22] |
| Staphylococcus aureus | Mouse Prosthetic joint infection/biofilm | Detrimental | [23–25] |
| Staphylococcus aureus | Mouse Skin infection | Detrimental | [26] |
| *Pseudomonas aeruginosa* | Human Cystic fibrosis lung infection | Correlative associated with preserved lung function | [27] |
| *Pseudomonas aeruginosa* | Mouse Lung infection (intranasal inoculation) | No significant impact on disease outcome | [28] |
| *Klebsiella pneumoniae* | Mouse Lung infection (intratracheal inoculation) | Beneficial | [29] |
| **Viral infections** | Hepatitis C virus | Humans Liver infection | Detrimental | [31] |
| Hepatitis B virus | Humans Liver infection | Beneficial | [33] |
| Human immunodeficiency virus-1 (HIV-1) | Humans Immune cells | Detrimental | [34–36] |
| **Parasitic infections** | *Leishmania major* | Mouse Footpad infection | Beneficial | [37] |
| *Trypanosoma cruzi* | Mouse Intraperitoneal infection | General beneficial, but can be also detrimental | [39] |
| *Schistosoma japonicum* | Mouse Percutaneous infection | Unknown | [41] |
| **Fungal infections** | *Candida albicans* | Humans and mouse Invasive infection (humans) and intravenous infection (mouse) | Beneficial | [42, 43] |
| *Aspergillus fumigatus* | Humans and immunosuppressed mice Invasive infection (humans) and intranasal infection (mouse) | Detrimental | [42] |
tuberculosis progression in mice that developed severe disease was associated with the replacement of Gr-1<sup>high</sup> Ly6G<sup>high</sup> conventional neutrophils by a population of Gr-1<sup>dim</sup> CD11b<sup>+</sup> cells that suppressed T-cell proliferation and IFN-gamma production in vitro via NO-dependent mechanisms and that resembled MDSC. The study of Knaul et al. [18] confirmed that excessive accumulation of MDSC in the lungs of <i>M. tuberculosis</i>-infected mice enhanced disease lethality and indicated that MDSC provided a niche for <i>M. tuberculosis</i> survival within the infected lungs.

Recruitment of both M-MDSC and PMN-MDSC from bone marrow into infected tissue has also been observed in mice infected with the Gram-negative pathogen <i>Salmonella enterica</i> serovar <i>Typhimurium</i>, which is a primary cause of food-borne infection that cause acute inflammatory diarrhea and can often progress to invasive systemic disease [19]. M-MDSC, in particular, were found to regulate T-cell responses during salmonella infection via NO production [19]. The authors suggested that during <i>S. typhimurium</i> infection, moderate amounts of M-MDSC provide protection from immune-medi- ated pathology, while accumulation of a high amount of these cells beyond a certain threshold may exert immunosuppressive functions that prolong the infection [19]. Defining the individual MDSC thresholds for different pathogens and infection types that separate beneficial (protective counter-regulatory) from harmful (overly immunosuppressive) MDSC functions remains a challenging task for the future.

An important role for MDSC has been reported in chronic infections caused by <i>Staphylococcus aureus</i>, a pathogen notorious for its capacity to cause difficult-to-treat chronic infections [20]. In murine models of <i>S. aureus</i> chronic abscess, gradual decline in the functionality of effector CD4<sup>+</sup> T cells has been shown to be associated with the progression of infection toward chronicity [21]. Expansion of MDSC was shown to be responsible for the progressive T-cell dysfunction and the failure to eliminate the pathogen [22]. Likewise, a critical role of MDSC in the establishment of chronic <i>S. aureus</i> biofilms in infected prosthetic joint was demonstrated by Heim et al. [23]. The authors showed that MDSC inhibited the pro-inflammatory activity of monocytes/macrophages in the infected joints as depletion of MDSC facilitated biofilm clearance by enhancing the proinflammatory functions of recruited monocytes [23]. Furthermore, the recruitment of MDSC to sites of <i>S. aureus</i> biofilm was mediated by IL-12 [24], and IL-10 released by recruited MDSC was responsible for the inhibition of the antimicrobial effect of monocytes/macrophages [25].

MDSC seems to further play an important role in immunomodulation during skin infections. Thus, it has been shown that cutaneous exposure to bacteria, such as <i>S. aureus</i> and specific bacterial products like TLR 2–6-binding diacylated lipopeptides, induce high IL-6 production by dermal cells leading to immunosuppression mediated by the recruitment of MDSC [26].

In other infection settings, the expansion of MDSC seems to be beneficial rather than detrimental to the host. For example, accumulation of PMN-MDSC has been observed in the lungs of cystic fibrosis patients with chronic <i>Pseudomonas aeruginosa</i> infection [27]. PMN-MDSC generation was induced through the stimulation of TLR5 in myeloid cells by <i>P. aeruginosa</i> flagellin. PMN-MDSC exerted an anti-inflammatory effect by suppressing polyclonal T-cell proliferation and modulation of Th17 responses [27]. The effect of <i>P. aeruginosa</i> infection on MDSC generation has also been demonstrated in vivo by another study [28]. A key role for MDSC in the regulation of lung inflammation was also described for acute bacterial pneumonia [29]. Using a murine model of <i>Klebsiella pneumoniae</i> acute lung infection, Poe et al. [29] demonstrated that MDSC contributed to resolution of lung inflammation via IL-10 production and efferocytosis of apoptotic cells.

**MDSC in Viral Infections**

Many viral infections often take a chronic course and one of the underlying mechanisms for viral persistence is the generation of MDSC [30]. Similar to bacterial infections, the elevated levels of proinflammatory cytokines and other inflammatory mediators may be the driven force for the expansion and recruitment of MDSC.

Hepatitis C is a liver infection caused by hepatitis C virus (HCV) that becomes chronic in a high percentage of infected individuals. It is widely accepted that T-cell responses play a pivotal role in the outcome of acute HCV infection and impaired T-cell responses have frequently been reported to be associated with chronic hepatitis C. In this regard, Tacke et al. [31] reported the presence of MDSC in the peripheral blood of individuals with chronic HCV infection. The authors also demonstrated that MDSC-induced, ROS-mediated immunosuppression of T-cells responses may facilitate and maintain HCV persistence [31]. Furthermore, HCV-induced MDSC were also shown to suppress the functionality of natural killer
cells, a cell population critical for controlling HCV infection by inhibiting viral replication and regulating adaptive immunity [32]. In this context, suppression was exerted by limiting the availability of L-arginine via the production of arginase-1 [32].

On the other hand, MDSC have been shown to exert a protective role in chronic infections caused by hepatitis B virus (HBV) [33]. In contrast to HCV, HBV is non-cytopathic for hepatocytes and the liver disease induced by HBV during chronic infection is immune mediated. Pallett et al. [33] reported a transient expansion of arginase-1-expressing PMN-MDSC in the circulation and liver of patients in whom HBV replicates high levels without inducing necroinflammatory liver disease. The authors propose a protective role for PMN-MDSC in maintaining immunotolerance in replicating HBV and ameliorating hepatic tissue damage in chronic HBV-infected patients [33].

Acquired immunodeficiency syndrome, caused by chronic infection with the human immunodeficiency virus-1 (HIV-1), is one of the most devastating pandemics of the 20th century. T-cells loss and dysfunction have been implicated in HIV-1 disease progression and evidence has been provided for a role of MDSC in the suppression of T-cell function in HIV-1-infected individuals. Thus, Vollbrecht et al. [34] reported high frequency of MDSC in HIV-1 infected cases that positively correlated with viral loads and negatively with CD4+ T cell numbers. The authors also found a fast drop in MDSC frequency upon starting antiretroviral therapy and concluded that MDSC during chronic HIV-1 infections contribute to the impaired T-cell responses characteristic for the progressive disease [34]. Likewise, Qin et al. [35] reported elevated levels of arginase-1 producing M-MDSC in peripheral blood of HIV-1 infected subjects that correlated with disease prognosis, HIV-1 loads and with T-cell loss and activation. Another study demonstrated that expansion of MDSC in HIV-infected individuals was mediated by high levels of IL-6 induced by the HIV envelop glycoprotein gp120 [36].

**MDSC in Parasitic Infections**

Beyond bacterial and viral infections, the expansion of MDSC has also been observed in different parasitic infections. Thus, it has been reported that although MDSC with a Gr-1highLy6ChighCD11bhighF4/80int phenotype, generated during acute infection with the sand fly-transmitted protozoan *Leishmania major*, can suppress T-cell responses, they are also capable of efficiently killing the parasite by producing high levels of NO and thereby contributing to parasite clearance [37]. Furthermore, treatment of *Leishmania*-infected mice with all-trans retinoic acid, a compound that drives the differentiation of MDSC into mature macrophages, resulted in increased development of lesions as well as increased parasite loads [37]. Although this study demonstrated that MDSC are beneficial in the effective control of *L. major* infection, another study [38] has reported that the mouse genetic background strongly influences the differentiation and function of MDSC during *L. major* infection. In this regard, MDSC derived from *L. major*-infected BALB/c mice exhibited higher parasite number compared with those derived from infected C57BL/6 mice [38].

Chagas disease, caused by the protozoan *Trypanosoma cruzi*, remains a major cause of morbidity and mortality in Latin America. Myocarditis, characterized by a mononuclear cell inflammatory infiltrate, is the most serious and frequent manifestation of chronic Chagas disease and affects approximately 30% of infected individuals. Cuervo et al. [39] demonstrated that MDSC expressing NO and arginase-1 were recruited into the heart of mice infected with *T. cruzi*. The authors further showed that MDSC are beneficial for host defense against *T. cruzi*, as they may regulate the excessive T-cell-dependent inflammation in the heart at the beginning of infection and produce NO required for efficient control of parasite loads in the heart [39]. However, persistent expression of NO in combination with arginase-1 by MDSC can also be detrimental for the host because it can cause extensive L-arginine depletion in plasma [39]. Similar to *L. major*, it has been reported that expansion and function of MDSC during infection with *T. cruzi* are influenced by the mouse genetic background [40]. Thus, a higher number of MDSC, in particular PMN-MDSC, was detected in the spleens and livers of infected BALB/c mice compared with infected C57BL/6 mice [40]. Since BALB/c mice present less inflammation and better survival than C57BL/6 mice after infection with *T. cruzi*, the authors concluded that MDSC seems to play a beneficial effect in infected BALB/c mice by contributing to reduction of parasite replication, enhancing the resolution of infection and preventing pathology associated with excessive inflammation [40].

It has also been proved that MDSC play a role in the pathogenesis of schistosomiasis, a chronic infection caused by a parasitic worm of the genus *Schistosoma* [41]. Specifically, the soluble egg Ag and schistosome worm antigen of *Schistosoma japonicum* was found to in-
duce the accumulation of MDSC in the spleen of infected mice by inducing the NADPH oxidase (NOX) subunits gp91phox and p47phox [41].

**MDSC in Fungal Infections**

In fungal infections, MDSC and PMN-MDSC in particular, have been shown to be protective in a murine model of systemic *Candida albicans* infection, but not in a model of pulmonary infection induced by the human pathogenic fungus *Aspergillus fumigatus* [42]. The underlying reasons for this differential role in fungal infections remain to be dissected in future investigations, but may be due to (i) yeast (*C. albicans*) versus filamentous (*A. fumigatus*) fungi, (ii) different routes of infection (systemic/intravenously for *C. albicans*; intranasally for *A. fumigatus*) or (iii) different fungal pathogen-associated molecular patterns. MDSC in *C. albicans* infection were induced through a mechanism involving fungal recognition through Dectin-1/CARD9 and the downstream mediators ROS and IL-1β [42]. The mechanisms underlying the beneficial effect mediated by MDSC in *C. albicans* infection are yet to be fully defined, but seemed to involve several cell types and mechanisms, including dampening of the pathogenic hyper-inflammatory NK and T-cell responses [42]. Further studies demonstrated that generation of MDSC was largely dependent of the *Candida* species and morphotype [43].

**Concluding Remarks**

Studies addressing the phenotypes and functions of MDSC in the setting of infection have grown tremendously during the last 2 decades. However, we have only just begun to understand the complex protective and harmful roles of these cells across a diverse range of infectious diseases. We have learned that MDSC are involved in the outcome of nearly every infection from bacteria to fungi, in particular during chronic infection, and also that they can be detrimental or of benefit for the host depending of the type of infection. Therefore, deeper knowledge about the role of MDSC in the different infection settings may eventually assist in designing treatments that will limit immunopathology, while preserving protective responses to these pathogens. Although the modulation of MDSC has emerged as an attractive option for the immunotherapy of different tumors and autoimmune diseases, more caution may be required for therapeutic targeting of MDSC in infection, since MDSC harbor phenotypic markers of both macrophages/monocytes and neutrophils, which are both critical for the control of many infectious pathogens.

**Disclosure Statement**

The authors have no conflicts of interest to declare.

**References**

1. Gabrilovich DI, Nagaraj S: Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162–174.
2. Youn JI, Gabrilovich DI: The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol 2010;40:2969–2975.
3. Goldmann O, Beineke A, Medina E: Identification of a novel subset of myeloid-derived suppressor cells during chronic staphylococcal infection that resembles immature Eosinophils. J Infect Dis 2017;216:1444–1451.
4. Mandruzzato S, Brandau S, Britten CM, Bronte V, Damuzio V, Gouttefangeas C, Maurer D, Ottensmeier C, van der Burg SH, Welters MJ, Walter S: Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study. Cancer Immunol Immunother 2016;65:161–169.
5. Obermaier N, Muthuswamy R, Lesnock J, Edwards RP, Kalinski P: Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood 2011;118:5498–5505.
6. Lechner MG, Liebertz DJ, Epstein AL: Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol 2010;185:2273–2284.
7. Cheng P, Corzo CA, Luetteke N, Yu B, Nagaraj S, Bui MM, Ortiz M, Nacken W, Sorg C, Vogl T, Roth J, Gabrilovich DI: Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 2008;205:2235–2249.
8. Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, Herber DL, Schneck J, Gabrilovich DI: Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 2007;13:828–835.
9. Rodriguez PC, Ochoa AC: Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev 2008;222:180–191.
10. Gabrilovich DI: Myeloid-Derived Suppressor Cells. Cancer Immunol Res 2017;5:3–8.
11. Condamine T, Gabrilovich DI: Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol 2011;32:19–25.
12. Ost M, Singh A, Peschel A, Mehlring R, Rieber N, Hartl D: Myeloid-derived suppressor cells in bacterial infections. Front Cell Infect Microbiol 2016;6:37.
13. Janols H, Berngenfelz C, Allauoi R, Larsson AM, Ryden L, Bjorntsson S, Janciauskiene S, Wullt M, Bredberg A, Leandersson K: A high frequency of MDSCs in sepsis patients, with the granulocytic subtype dominating in granulo-positive cases. J Leukoc Biol 2014;96:685–693.
14. Gabrilovich DI: Editorial: The intricacy of choice: can bacteria decide what type of myeloid cells to stimulate? J Leukoc Biol 2014;96:671–674.
15 Periasamy S, Avram D, McCabe A, MacNamara KC, Sellati TJ, Harton JA: An immature myeloid/myeloid-suppressor cell response associated with necrotizing inflammation mediates lethal pulmonary tularemia. PLoS Pathog 2016;12:e1005517.
16 du Plessis N, Loebenberg L, Kriel M, von Grooto-Billingmaier F, Ribechini E, Loxton AG, van Helden PD, Lutz MB, Walzl G: Increased frequency of myeloid-derived suppressor cells during active tuberculosis and after recent mycobacterium tuberculosis infection suppresses T-cell function. Am J Respir Crit Care Med 2013;188:724–732.
17 Tsiganov EN, Verbina EM, Radaeva TV, Sozova VF, Kosmiadi GA, Nikitina IY, Lyadova IV: Gr-1dimCD11b+ immature myeloid-derived suppressor cells but not neutrophils are markers of lethal tuberculosis infection in mice. J Immunol 2014;192:4718–4727.
18 Knoll JC, Vorgl D, Oberbeck-Mueller D, Heinemann E, Scheuermann L, Brinkmann V, Mollenkopf HJ, Yermeev V, Kaufmann SH, Dorhoi A: Lung-residing myeloid-derived suppressor cells display dual functionality in murine pulmonary tuberculosis. Am J Respir Crit Care Med 2014;190:1053–1066.
19 Tam JW, Kullas AL, Mena P, Bliska JB, van der Velden AW: CD11b+ Ly6Chi Ly6G- immature myeloid cells recruited in response to Salmonella enterica serovar Typhimurium infection exhibit protective and immunosuppressive properties. Infect Immun 2014;82:2606–2614.
20 Conlon BP: Staphylococcus aureus chronic and relapsing infections: evidence of a role for persister cells: an investigation of persister cells, their formation and their role in S. aureus disease. Bioessays 2014;36:991–996.
21 Ziegler C, Goldmann O, Hobeika E, Geffers R, Peters G, Medina E: The dynamics of T cells during persistent Staphylococcus aureus infection: from antigen-reactivity to in vivo anergy. EMBO Mol Med 2011;3:652–666.
22 Tebartz C, Horst SA, Sparwasser T, Huehn J, Beineke A, Peters G, Medina E: A major role for myeloid-derived suppressor cells and a minor role for regulatory T cells in immune suppression during Staphylococcus aureus infection. J Immunol 2015;194:1100–1111.
23 Heim CE, Vidlak D, Scherr TD, Kozel JA, Holzapfel M, Mairhead DE, Kielen T: Myeloid-derived suppressor cells contribute to Staphylococcus aureus orthopedic biofilm infection. J Immunol 2014;192:3778–3792.
24 Heim CE, Vidlak D, Scherr TD, Hartman CW, Garvin KL, Kielen T: IL-12 promotes myeloid-derived suppressor cell recruitment and bacterial persistence during Staphylococcus aureus orthopedic implant infection. J Immunol 2015;194:3861–3872.
25 Heim CE, Vidlak D, Kielen T: Interleukin-10 production by myeloid-derived suppressor cells contributes to bacterial persistence during Staphylococcus aureus orthopedic biofilm infection. J Leukoc Biol 2015;98:1003–1013.
26 Skabrys Y, Wolbing F, Gunther C, Koerber M, Kaesler S, Chen KM, Guenova E, Demircioglu D, Kempf WE, Voltz T, Ramnassen HG, Schaller M, Rocken M, Gotz F, Biedermann T: Cutaneous innate immune sensing of Toll-like receptor 2–6 ligands suppresses T cell immunity by inducing myeloid-derived suppressor cells. Immunity 2014;41:762–775.
27 Rieber N, Brand A, Hector A, Graepel-Mainka U, Ost M, Schafer I, Wecker I, Neri D, Wirth A, Mays L, Zundel S, Fuchs J, Handgretier R, Stern M, Hogardt M, Doring G, Riethmüller J, Kormann M, Hartl D: Flagellin induces myeloid-derived suppressor cells: implications for Pseudomonas aeruginosa infection. Infect Immun 2013;81:1276–1284.
28 Oz HH, Zhou B, Voss P, Carevic M, Schroth C, Frey N, Rieber N, Hector A, Hartl D: Pseudomonas aeruginosa airway infection recruits and modulates neutrophilic myeloid-derived suppressor cells. Front Cell Infect Microbiol 2016;6:167.
29 Poe SL, Aziz MA, Oris TB, Polyak SJ, Rosen HR, Hahn YS: Myeloid suppressor cells participate in defense against virus-induced myeloid-derived suppressor cells. Nat Med 2015;21:591–600.
30 Vollbrecht T, Stirm R, Tufman A, Roeder J, Huber RM, Bogner JR, Lechner A, Bourquin C, Draenert R: Chronic progressive HIV-1 infection is associated with elevated levels of myeloid-derived suppressor cells. AIDS 2012;26:F31–37.
31 Qiu A, Cai W, Pan T, Wu K, Yang Q, Wang N, Liu Y, Yan D, Hu F, Guo P, Chen X, Chen L, Zhang H, Tang X, Zhou J: Expansion of monocytic myeloid-derived suppressor cells dampens T cell function in HIV-1-seropositive individuals. J Virol 2013;87:1477–1490.
32 Garg A, Spector SA: HIV type 1 gp120–induced expansion of myeloid derived suppressor cells is dependent on interleukin 6 and suppresses immunity. J Infect Dis 2014;209:441–451.
33 Pereira WF, Ribeiro-Gomes FL, Guarinello LV, Velloso NS, MONTALVAO F, Dosreis GA, Lopes MF: Myeloid-derived suppressor cells help protective immunity to Leishmania major infection despite suppressed T cell responses. J Leukoc Biol 2011;90:1191–1197.
34 Schmid M, Zimara N, Wege AK, Rüter U: Myeloid-derived suppressor cell functionality and interaction with Leishmania major parasites differ in C57BL/6 and BALB/c mice. Eur J Immunol 2014;44:3295–3306.
35 Cuervo H, Guerra O, Carballo M, Read AJ, Lai S, Gea S: Myeloid-derived suppressor cells infiltrate the heart in acute Trypanosoma cruzi infection. J Immunol 2011;187:2656–2665.
36 Arocena AR, Onofrio LI, Pellegrini AV, Carrera Silva AE, Paroli A, Cano RC, Aoki MP, Gea S: Myeloid-derived suppressor cells are key players in the resolution of inflammation during a model of acute infection. Eur J Immunol 2014;44:184–194.
37 Yang Q, Qiu H, Xie H, Qi Y, Cha H, Qi J, Wang M, Feng Y, Ye X, Mu J, Huang F: A Schistosoma japonicum infection promotes the expansion of myeloid-derived suppressor cells by activating the JAK/STAT3 pathway. J Immunol 2017;198:4716–4727.
38 Rieber N, Singh A, Os H, Carevic M, Bouzani M, Amich J, Ost M, Ye Z, Balbach M, Schafer I, Messer M, Klimosch SN, Weber AN, Handgretier R, Krappmann S, Liese J, Engelhom M, Schue R, Sahli HR, Marodi L, Speckmann C, Grimbacher B, Ruland J, Brown GD, Beilhack A, Loeffler J, Hartl D: Pathogenic fungi regulate immunity by inducing neutrophilic myeloid-derived suppressor cells. Cell Host Microbe 2015;17:507–514.
39 Singh A, Lelis F, Braig S, Schafer J, Hartl D: Rieber N: Differential regulation of myeloid-derived suppressor cells by Candida species. Front Microbiol 2016;7:1624.